Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance

Li, Yanqing; Jiao, Yan; Li, Yang; Liu, Yanan

doi:https://doi.org/10.1155/2019/1569049

Disease Markers

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2019 | Article ID 1569049 | https://doi.org/10.1155/2019/1569049

Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance

Yanqing Li,¹Yan Jiao,²Yang Li,¹and Yanan Liu¹

Academic Editor: Paola Gazzaniga

Received25 Apr 2019

Accepted17 Sept 2019

Published22 Oct 2019

Abstract

Background and Objective. Liver cancer is a common malignant tumor with few poor diagnostic and prognostic markers, which greatly shortens the potential life span of patients. The RNA-binding protein la ribonucleoprotein 4B (LARP4B) has a la motif (lam) that is important in the process of cancer. We aimed to explore the role of LARP4B in the diagnosis and prognosis of liver cancer. Methods. The Cancer Genome Atlas (TCGA) database was searched to detect LARP4B gene expression in liver cancer. The clinical relevance and diagnostic ability of LARP4B were evaluated by a chi-squared test and a receiver operating characteristic (ROC) curve, respectively. Survival and risk factors of patients with liver cancer were assessed by survival analysis and univariate/multivariate Cox regression model. Additionally, we carried out gene set enrichment analysis (GSEA) to identify LARP4B-related signaling pathways in liver cancer. Results. LARP4B mRNA was highly expressed in liver cancer tissues and was correlated with survival status. The chi-squared test showed that LARP4B had clinical relevance, while ROC curves showed that LARP4B had good diagnostic ability. Survival analysis showed that liver cancer patients with high LARP4B expression had shorter overall/relapse-free survival. The univariate/multivariate Cox regression model indicated that high LARP4B expression may be an independent risk factor for the prognosis of liver cancer patients. Finally, we found that genes involved in the G2M checkpoint, E2F targets, and mitotic spindle were differentially enriched in the high LARP4B-expression phenotype. Conclusions. LARP4B is a potential independent biomarker for diagnosis and prognosis in liver cancer patients.

1. Introduction

Liver cancer is one of the most common malignant tumors in the world [1]. It has a high degree of malignancy, strong invasion and metastasis, and poor prognosis and poses a serious threat to health [2]. Although the number of tumor markers used in the diagnosis and prognosis of related cancers has increased, none have the high recognition, sensitivity, and specificity required to evaluate the condition, efficacy, and prognosis of liver cancer [3, 4]. There is an urgent need to identify biomarkers with diagnostic and prognostic accuracy.

La ribonucleoprotein 4B (LARP4B) is a member of the La-related protein (LARP) family [5]. LARP4B protein is an RNA-binding protein containing lanthanum and adjacent RNA recognition motifs (RRMs) [6], which allow it to participate in posttranscriptional control of RNA and play an important role in translation [7, 8]. LARP4B is involved in the progression of many cancers [9]. In gliomas, for example, LARP4B inhibits tumor progression [10]. However, its role in liver cancer has not been explored.

To assess the potential clinical role of LARP4B in liver cancer, we probed TCGA database for the mRNA expression of LARP4B in liver cancer patients. Chi-squared testing was used to assess clinical relevance, ROC curves were used to estimate diagnostic capability, and overall/relapse-free survival analyses were conducted to examine the impact of LARP4B on patients with liver cancer. Univariate/multivariate Cox regression models were used to identify risk factors associated with liver cancer. We also carried out GSEA about the LARP4B-related signaling pathways.

2. Materials and Methods

2.1. Data Source

We obtained currently available clinical and RNA sequence data about normal and liver cancer tissues from TCGA (https://cancergenome.nih.gov/). No ethical permission was required because all of the data used in this paper were made available for research.

2.2. Data Mining and Statistical Analyses

We used the R software environment (version 3.6.1) for data mining [11]. Boxplots of clinical features were drawn with the ggplot2 package [12]. The ROC curve was drawn by pROC [13], which is based on a series of different binary classifications (demarcation value or determination threshold), plotting the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa. Among them, the area under the ROC curve (AUC) is used to measure the diagnostic performance. The chi-squared test was used to identify possible clinical correlations between clinical features and LARP4B expression. We also used survival packages to plot survival curves, and a logarithmic rank test to check survival bias [14]. Univariate and multivariate Cox models were used to distinguish risk factors associated with liver cancer [15].

2.3. GSEA

GSEA is used to classify gene probes based on related biological pathways published in authoritative journals and coexpression data obtained from experiments. To determine correlation, a series of operations are carried out to determine whether the probes can reveal a distribution pattern of genes related to the phenotype of interest [16]. In this research, we used the gene set of “h.all.v6.2.symbols.gmt” from the Molecular Signatures Database to perform GSEA in GSEA 3.0 software. Through the analysis of 1,000 permutations, we obtained the standardized enrichment fraction and calculated a normalized enrichment score.

3. Results

3.1. Data Overview

The LARP4B expression level and clinical features of the TCGA liver cancer cohort include gender, age, histologic type and grade, sample type, T/N/M classification, radiation therapy, residual tumor, vital status, stage, and relapse (Table 1).

3.2. LARP4B Expression in Normal and Liver Cancer Tissues

Boxplots showed higher LARP4B mRNA expression in liver cancer tissues compared with normal liver tissues (; Figure 1). Furthermore, there were significant differences in LARP4B expression with regard to vital status (), stage (), gender (), age (), histologic grade (), type (), and T classification ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

3.3. Diagnostic Capability of LARP4B in Liver Cancer

ROC curves revealed that AUC was 0.816, indicating that LARP4B might have considerable diagnostic ability (Figure 2(a)). This result was confirmed in subsequent subgroup analysis of the different stages (AUC: 0.784, 0.795, 0.884, and 0.872 for stage I, stage II, stage III, and stage IV, respectively; Figures 2(b)–2(e)).

(a)

(b)

(c)

(d)

(e)

3.4. High LARP4B Expression Was Relevant to Clinical Features of Liver Cancer

As shown in Table 2, the expression of LARP4B was clearly related to age (), gender (), vital status (), and histologic grade () of liver cancer patients.

3.5. Increased LARP4B Expression Was Related to Poor Overall Survival in Liver Cancer

As shown in Figure 3, the high expression of LARP4B in patients was correlated with poor overall survival (). Subgroup analysis showed that LARP4B expression had significant prognostic value in liver cancer patients who were older (), T3 (), G1/G2 (), male (), and R0 ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

A univariate Cox model revealed that residual tumor, stage, T classification, and LARP4B expression represented potential survival-related variables. A multivariate Cox model suggested that a high LARP4B expression was a potential independent risk factor for patient’s overall survival with liver cancer (95% confidence interval (CI) 1.1–2.46, , ; Table 3).

3.6. Increased LARP4B Expression Was Related to Poor Relapse-Free Survival in Liver Cancer

As shown in Figure 4, there was a high expression of LARP4B in patients with relapse-free survival (). Subgroup analysis showed that LARP4B expression had a prognostic value in liver cancer patients who were T4 (), male (), stage III/IV (), G1/G2 (), and older ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

A univariate Cox model showed that residual tumor, stage, T classification, and LARP4B expression represented potential relapse-free survival-related variables. A multivariate Cox model suggested that a high LARP4B expression was a potential independent risk factor for relapse-free survival in liver cancer patients (95% CI 1–2.13, , ; Table 4).

3.7. LARP4B-Related Signaling Pathway

To identify the activated signal pathways in liver cancer, GSEA was conducted between the low LARP4B expression and high LARP4B expression datasets. GSEA revealed significant differences in the enrichment of the MSigDB Collection (h.all.v6.2.symbols.gmt; NOM value < 0.05, ; Table 5). Genes related to E2F, G2M, and the mitotic spindle (Figure 5; Table 5) were enriched in the high LARP4B expression phenotype, which may represent an intrinsic mechanism of poor prognosis.

(a)

(b)

(c)

4. Discussion

Viral infection, diet, environmental problems, and other factors have contributed to the high mortality rate of liver cancer worldwide [17]. Continuous advances in surgical technology, chemotherapeutic drugs, and molecular biology have furthered our understanding of cancer biology, and there has been great progress in the treatment of liver cancer in recent years. In this study, we have applied our extensive experience in the exploration of novel biomarkers [18–23] to identify a biomarker, LARP4B, for the diagnosis and prognosis of patients with liver cancer.

The involvement of LARP4B has been documented in many cancer processes, including medulloblastoma [24], malignant peripheral nerve sheath tumors [25], colorectal cancer [26], pancreatic cancer [27], and glioma [10]. In contrast to our results, Koso et al. [10] found low expression of LARP4B in gliomas, which suggests that LARP4B may play different roles in different cancers. In addition, the boxplots showed that LARP4B expression was statistically significantly associated with vital status, age, gender, histologic grade and type, stage, and T classification. Therefore, it is necessary to further explore the role of LARP4B in liver cancer.

Low LARP4B expression was closely related to poor prognosis in glioma cancer patients in the study by Koso et al. [10]. No such relationship between LARP4B and prognosis has been found in liver cancer. In this study, we found that overexpressed LARP4B was associated with a poor prognosis in liver cancer patients, which may be attributable to the different functions of LARP4B in different tissues. LARP4B overexpression also led to shorter overall/relapse-free survival. Subgroup analysis of overall survival showed especially poor prognoses in patients who were male, T3, G1/G2, older, and R0, while relapse-free survival was correlated with patients who were male, T4, G1/G2, older, and stage III/IV. This distinction could be applied to the precise, individualized treatment of liver cancer patients. Calculation of AUC from the ROC curves showed the validity of clinical diagnostic testing of LARP4B. Our results suggest that LARP4B has strong potential as a marker in the clinical detection of liver cancer patients.

The progression of cancer requires a complete cell cycle [28]. Genes related to E2F, G2M, and the mitotic spindle are important signaling pathways in the cell cycle [29–31]. Interestingly, we found that E2F, G2M, and mitotic spindle signaling pathways were all involved in the progression of liver cancer. LARP4B is a posttranscriptional regulator and may regulate the roles of downstream genes through these three sets of target molecules. In addition, Zhang et al. [32] found that LARP4B may regulate the cell cycle of leukemia stem cells by inhibiting the expression of cell cycle inhibitors p16, P19, and p21 and myeloid-specific transcription factor CCAAT enhancer binding protein alpha. However, Mattijssen and Maraia [33] found that LARP4B participated in the regulation of TNF-alpha-TTP as its functional activity in MLL-AF9 leukemia stem cells. It is possible that LARP4B participates in the progression of different cancers through multiple signaling pathways.

As far as we know, this is the first study to examine the diagnostic and prognostic values of LARP4B expression in liver cancer. Together with other studies on the functions of LARP4B, we have contributed to a better understanding of the role of LARP4B and expanded the possibilities for more precise diagnosis and prognosis in cancer. We plan to continue exploring the functions of LARP4B to clarify its underlying mechanism in tumorigenesis at a deeper level.

5. Conclusion

In this investigation of LARP4B in the prognosis and diagnosis of liver cancer, we identified high LARP4B expression as a potential independent biomarker for negative prognosis. We have plans for complex experiments to explore the mechanism further.

Data Availability

We obtained patient information from an open TCGA database. No private clinical studies or patient data were included in this study.

Conflicts of Interest

None of the authors have any conflicts of interest.

Acknowledgments

We thank Michelle Kahmeyer-Gabbe, PhD, from Liwen Bianji, Edanz Editing China (http://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript. The project was funded by the Bethune Program of Jilin University (2018A02), Jilin Department of Health (2018J061), and basic research fees.

References

R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
View at: Publisher Site | Google Scholar
K. A. Cronin, A. J. Lake, S. Scott et al., “Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics,” Cancer, vol. 124, no. 13, pp. 2785–2800, 2018.
View at: Publisher Site | Google Scholar
L. Li and H. Wang, “Heterogeneity of liver cancer and personalized therapy,” Cancer Letters, vol. 379, no. 2, pp. 191–197, 2016.
View at: Publisher Site | Google Scholar
J. Dawkins and R. M. Webster, “The hepatocellular carcinoma market,” Nature Reviews Drug Discovery, vol. 18, no. 1, pp. 13-14, 2019.
View at: Google Scholar
M. F. Bonaldo, G. Lennon, and M. B. Soares, “Normalization and subtraction: two approaches to facilitate gene discovery,” Genome Research, vol. 6, no. 9, pp. 791–806, 1996.
View at: Publisher Site | Google Scholar
C. Bousquet-Antonelli and J. M. Deragon, “A comprehensive analysis of the La-motif protein superfamily,” RNA, vol. 15, no. 5, pp. 750–764, 2009.
View at: Publisher Site | Google Scholar
M. A. Bayfield, R. Yang, and R. J. Maraia, “Conserved and divergent features of the structure and function of La and La-related proteins (LARPs),” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1799, no. 5-6, pp. 365–378, 2010.
View at: Publisher Site | Google Scholar
A. Castello, B. Fischer, K. Eichelbaum et al., “Insights into RNA biology from an atlas of mammalian mRNA-binding proteins,” Cell, vol. 149, no. 6, pp. 1393–1406, 2012.
View at: Publisher Site | Google Scholar
C. Stavraka and S. Blagden, “The La-related proteins, a family with connections to cancer,” Biomolecules, vol. 5, no. 4, pp. 2701–2722, 2015.
View at: Publisher Site | Google Scholar
H. Koso, H. Yi, P. Sheridan et al., “Identification of RNA-binding protein LARP4B as a tumor suppressor in glioma,” Cancer Research, vol. 76, no. 8, pp. 2254–2264, 2016.
View at: Publisher Site | Google Scholar
Team RDCJC, R : A language and environment for statistical computing, vol. 14, R Foundation for Statistical Computing, Vienna, Austria, 2009.
C. Ginestet, “ggplot2: elegant graphics for data analysis,” Journal of the Royal Statistical Society: Series A (Statistics in Society), vol. 174, no. 1, pp. 245-246, 2011.
View at: Publisher Site | Google Scholar
X. Robin, N. Turck, A. Hainard et al., “pROC: an open-source package for R and S+ to analyze and compare ROC curves,” BMC Bioinformatics, vol. 12, no. 1, p. 77, 2011.
View at: Publisher Site | Google Scholar
T. M. Therneau, “A package for survival analysis in S. 2015,” R Package Version, vol. 2, p. 280, 2017.
View at: Google Scholar
T. M. Therneau and P. M. Grambsch, Modeling Survival Data: Extending the Cox Model, vol. 97, Springer, New York, 2000.
View at: Publisher Site
A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005.
View at: Publisher Site | Google Scholar
A. B. Ryerson, C. R. Eheman, S. F. Altekruse et al., “Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer,” Cancer, vol. 122, no. 9, pp. 1312–1337, 2016.
View at: Publisher Site | Google Scholar
Y. Jiao, Z. Fu, Y. Li, L. Meng, and Y. Liu, “High EIF2B5 mRNA expression and its prognostic significance in liver cancer: a study based on the TCGA and GEO database,” Cancer Management and Research, vol. 10, pp. 6003–6014, 2018.
View at: Publisher Site | Google Scholar
Y. Jiao, Z. Fu, Y. Li, W. Zhang, and Y. Liu, “Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer,” PloS One, vol. 14, no. 1, p. e0211291, 2019.
View at: Publisher Site | Google Scholar
Y. Jiao, Y. Li, Z. Lu, and Y. Liu, “High trophinin-associated protein expression is an independent predictor of poor survival in liver cancer,” Digestive Diseases and Sciences, vol. 64, no. 1, pp. 137–143, 2019.
View at: Publisher Site | Google Scholar
M. I. Almeida, M. S. Nicoloso, L. Zeng et al., “Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells,” Gastroenterology, vol. 142, no. 4, pp. 886–896.e889, 2012.
View at: Publisher Site | Google Scholar
Y. Jiao, Y. Li, S. Liu, Q. Chen, and Y. Liu, “ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer,” OncoTargets and Therapy, vol. 12, pp. 4141–4152, 2019.
View at: Publisher Site | Google Scholar
Y. Li, Y. Jiao, Z. Fu, Z. Luo, J. Su, and Y. Li, “High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma,” Cancer Management and Research, vol. 11, pp. 2795–2802, 2019.
View at: Publisher Site | Google Scholar
X. Wu, P. A. Northcott, A. Dubuc et al., “Clonal selection drives genetic divergence of metastatic medulloblastoma,” Nature, vol. 482, no. 7386, pp. 529–533, 2012.
View at: Publisher Site | Google Scholar
E. P. Rahrmann, A. L. Watson, V. W. Keng et al., “Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis,” Nature Genetics, vol. 45, no. 7, pp. 756–766, 2013.
View at: Publisher Site | Google Scholar
H. Takeda, Z. Wei, H. Koso et al., “Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression,” Nature Genetics, vol. 47, no. 2, pp. 142–150, 2015.
View at: Publisher Site | Google Scholar
P. A. Pérez-Mancera, A. G. Rust, L. van der Weyden et al., “The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma,” Nature, vol. 486, no. 7402, pp. 266–270, 2012.
View at: Google Scholar
P. Icard, L. Fournel, Z. Wu, M. Alifano, and H. Lincet, “Interconnection between metabolism and cell cycle in cancer,” Trends in Biochemical Sciences, vol. 44, no. 6, pp. 490–501, 2019.
View at: Publisher Site | Google Scholar
M. Fischer and G. A. Muller, “Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes,” Critical Reviews in Biochemistry and Molecular Biology, vol. 52, no. 6, pp. 638–662, 2017.
View at: Publisher Site | Google Scholar
R. Fraschini, “Factors that control mitotic spindle dynamics,” Advances in Experimental Medicine and Biology, vol. 925, pp. 89–101, 2017.
View at: Publisher Site | Google Scholar
A. Krempler, D. Deckbar, P. A. Jeggo, and M. Lobrich, “An Imperfect G2M Checkpoint Contributes to Chromosome Instability Following Irradiation of S and G2Phase Cells,” Cell Cycle, vol. 6, no. 14, pp. 1682–1686, 2007.
View at: Publisher Site | Google Scholar
Y. Zhang, L. Peng, T. Hu et al., “La-related protein 4B maintains murine MLL-AF9 leukemia stem cell self-renewal by regulating cell cycle progression,” Experimental Hematology, vol. 43, no. 4, pp. 309–318.e302, 2015.
View at: Publisher Site | Google Scholar
S. Mattijssen and R. J. Maraia, “LARP4 is regulated by tumor necrosis factor alpha in a tristetraprolin-dependent manner,” Molecular and Cellular Biology, vol. 36, no. 4, pp. 574–584, 2016.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2019 Yanqing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

815

Downloads

939

Citations